ELOX

Eloxx Pharmaceuticals (ELOX)

About Eloxx Pharmaceuticals (ELOX)

Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid-modulating drug candidates. The firm focuses on the the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. Its lead product candidate is ELX-02, a small molecule drug designed to restore production of full-length functional proteins. It operates through the United States and Israel geographical segments. The company was founded by Silvia Noiman on December 19, 2017 and is headquartered in Watertown, MA.

Details

Daily high
$0.00
Daily low
$0.00
Price at open
$0.00
52 Week High
$4.29
52 Week Low
$0.00
Market cap
300
Dividend yield
0.00%
Volume
216,145
Avg. volume
419
P/E ratio
.00

Eloxx Pharmaceuticals News

Details

Daily high
$0.00
Daily low
$0.00
Price at open
$0.00
52 Week High
$4.29
52 Week Low
$0.00
Market cap
300
Dividend yield
0.00%
Volume
216,145
Avg. volume
419
P/E ratio
.00